Ippokrateio General Hospital of Thessaloniki is a public hospital in Thessaloniki, Greece. The main building was constructed in 1908 as "Hirsch Hospital" funded by Maurice de Hirsch. During the Axis occupation of Greece it was used by the German army. It was renamed after World War II.

During the past decade, Hippokration General Hospital of Thessaloniki conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 23 clinical trials were completed, i.e. on average, 32.9% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 18 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hippokration General Hospital of Thessaloniki" #1 sponsor was "Bayer" with 10 trials, followed by "Celgene" with 7 trials sponsored, "Pfizer" with 6 trials sponsored, "Amgen" with 5 trials sponsored and "Boehringer Ingelheim" with 5 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hippokration General Hospital of Thessaloniki" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "AiCuris Anti-infective Cures AG" with 1 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Hippokration General Hospital of Thessaloniki" are "Acromegaly" (5 trials), "Crohn Disease" (4 trials), "Heart Failure" (3 trials), "Atrial Fibrillation" (2 trials) and "Candidemia" (2 trials). Many other conditions were trialed in "Hippokration General Hospital of Thessaloniki" in a lesser frequency.

Most popular intervention types in "Hippokration General Hospital of Thessaloniki" are "Drug" (70 trials), "Other" (12 trials), "Biological" (6 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Ozanimod" (3 trials), "Paltusotine" (3 trials), "Soticlestat" (3 trials) and "Apremilast" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hippokration General Hospital of Thessaloniki" are 77 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hippokration General Hospital of Thessaloniki". undefined are not yet recruiting, 31 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Hippokration General Hospital of Thessaloniki, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hippokration General Hospital of Thessaloniki, 3 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".